The Arg allele in position 192 of PON1 is associated with carotid atherosclerosis in subjects with elevated HDLs

Atherosclerosis

Volumn 164, Issue 2, 2002, Pages 289-295

  Gnasso, Agostino ^a   Motti, Corradino ^a   Irace, Concetta ^a   Di Gennaro, Immacolata ^a   Pujia, Arturo ^a   Leto, Elio ^a   Ciamei, Monica ^a   Crivaro, Andrea ^a   Bernardini, Sergio ^a   Federici, Giorgio ^a   Cortese, Claudio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Atherosclerosis; Carotid arteries; Genetics; High density lipoproteins; Paraoxonase; Ultrasound

Indexed keywords

ARGININE; ARYLDIALKYLPHOSPHATASE; GLUCOSE; GLUTAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; ALCOHOL CONSUMPTION; ALLELE; AMINO ACID SEQUENCE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY WEIGHT; CAROTID ARTERY; CAROTID ARTERY DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ECHOGRAPHY; ENZYMATIC ASSAY; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MODEL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RESTRICTION MAPPING; RISK ASSESSMENT; SCORING SYSTEM; SEX RATIO; SMOKING;

ADULT; ALLELES; ANALYSIS OF VARIANCE; ARGININE; ARYLDIALKYLPHOSPHATASE; BASE SEQUENCE; CAROTID ARTERY DISEASES; CHOLESTEROL, HDL; COHORT STUDIES; CONFIDENCE INTERVALS; ESTERASES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROBABILITY; RISK ASSESSMENT; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; ULTRASONOGRAPHY, DOPPLER;

EID: 0036801786     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00070-9     Document Type: Article

References (29)

1. La Du B.N., Adkins S., Kuo C.L., Lipsig D. Studies on human serum paraoxonase/arylesterase. Chem. Biol. Interact. 87:1993;25-34.
2. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Fault K.F., Fogelman A.M., Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidised low density lipoprotein. J. Clin. Invest. 96:1995;2882-2891.
3. Shih D.M., Gu L., Xia Y.R., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394:1998;284-287.
4. Primo-Parmo S.L., Sorenson R.C., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 33:1996;498-507.
5. Adkins S., Gan K.N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 52:1993;598-608.
6. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3:1993;73-76.
7. Leviev I., James R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20:2000;516-521.
8. Mackness M.I., Mackness B., Durrington P.N., et al. Paraoxonase and coronary heart disease. Curr. Opin. Lipidol. 9:1998;319-324.
9. Mackness B., Mackness M.I., Arrol S., Turkie W., Durrington P.N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 423:1998;57-60.
10. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parno S.L., La Du B. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101:1998;1581-1590.
11. Aviram M., Hardak E., Vaya J., et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 101:2000;2510-2517.
12. Cao H., Girard-Globa A., Berthezene F., Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism. J. Lipid Res. 40:1999;133-139.
13. Barbagallo C.M., Averna M.R., Novo S., et al. Apo-lipoprotein profile in subjects with extracranial carotid atherosclerosis. Int. Angiol. 13:1994;223-228.
14. Sharrett A.R., Sorlie P.D., Chambless L.E., Folsom A.R., Hutchinson R.G., Heiss G., Szklo M. Relative importance of various risk factors for asymptomatic carotid atherosclerosis versus coronary heart disease incidence: The Atherosclerosis Risk in Communities Study. Am. J. Epidemiol. 149:1999;843-852.
15. Gnasso A., Calindro M.C., Carallo C., et al. Awareness, treatment and control of hyperlipidaemia, hypertension and diabetes mellitus in a selected population of southern Italy. Eur. J. Epidemiol. 13:1997;421-428.
16. Rose G.A. The diagnosis of ischemic heart pain and intermittent claudication in field surveys. Bull. WHO. 27:1962;645-658.
17. Furlong C.E., Costa L.G., Hassett C., et al. Human and rabbit paraoxonases: Purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem. Biol. Interact. 87:1993;35-48.
18. Strandness D.E. Jr. Non-invasive evaluation of arteriosclerosis. Comparison of methods. Arteriosclerosis. 3:1983;103-116.
19. Gnasso A., Irace C., Carallo C., De Franceschi M.S., Motti C., Mattioli P.L., Pujia A. In vivo association between low wall shear stress and plaque in subjects with asymmetrical carotid atherosclerosis. Stroke. 28:1997;993-998.
20. Dessì M., Gnasso A., Motti C., et al. Influence of the human paraoxonase polymorphism (PON1 192) on the carotid-wall thickening in a healthy population. Coron. Artery Dis. 10:1999;595-599.
21. Cao H., Girard-Globa A., Serusclat A., et al. Lack of association between carotid intima-media thickness and paraoxonase gene polymorphism in non-insulin dependent diabetes mellitus. Atherosclerosis. 138:1998;361-366.
22. Schmidt H., Schmidt R., Niederkorn K., et al. Paraoxonase PON1 polymorphism Leu-Met54 is associated with carotid atherosclerosis. Stroke. 29:1998;2043-2048.
23. Leus F.R., Wittekoek M.E., Prins J., Kastelein J.J., Voorbij H.A. Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia. Atherosclerosis. 149:2000;371-377.
24. James R.W., Blatter Garin M.C., Calabresi L., et al. Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. Atherosclerosis. 139:1998;77-82.
25. Ombres D., Pannitteri G., Montali A., Candeloro A., Seccareccia F., Campagna F., Cantini R., Campa P.P., Ricci G., Arca M. The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler. Thromb. Vasc. Biol. 18:1998;1611-1616.
26. Pfohl M., Koch M., Enderle M.D., Kuhn R., Fullhase J., Karsch K.R., Haring H.U. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes. 48:1999;623-627.
27. Ruiz J., Blanche H., James R.W., et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346:1995;869-872.
28. Richter R.J., Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics. 9:1999;745-753.
29. Mackness B., Davies G.K., Turkie W., et al. Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 21:2001;1451-1457.